Physician profile
Eric E Drolshagen
NPI 1598285181
$8,348.03
in general payments reported to CMS, 2019-2025
34 companies · $2,036 in 2025
The $2,036 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.24 · 2021: $1,183 · 2022: $1,286 · 2023: $1,632 · 2024: $2,191 · 2025: $2,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,859.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.10 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $1,501.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $633.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $572.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $527.42 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $468.44 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $372.61 | 2021-2024 | |
| Glaxosmithkline, LLC. | $302.33 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $241.54 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $217.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $199.10 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $168.85 | 2021-2024 | |
| Eisai INC. | $146.74 | 2021 | |
| Abiomed | $133.16 | 2024 | Impella |
| Stryker Corporation | $121.46 | 2025 | Flowtriever |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Drolshagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.